Clinical trial

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

NCT03356769

Study summary

ClinicalTrials.gov

Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Aspirin Normalized identity: aspirin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention AED Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-11-20

PhasePHASE2

Conditions

Tuberous Sclerosis Complexverified · MONDO: tuberous sclerosis

Aspirinunresolved

Epilepsyverified · MONDO: epilepsy

Cognitive Declineunresolved

Skin Lesionsunresolved

Interventions

AspirinDRUG · verified · RxNorm: aspirin

AEDDRUG

PlaceboDRUG

Sponsors & collaborators

Peking Union Medical College Hospitallead sponsor

Shijiazhuang Yiling Pharmaceutical Co. Ltdcollaborator

Mapped research locations

BeijingBeijing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03356769 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.